Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Wayfair Poised For Q2 Sales Beat On Strong Inventory, Vendor Promotions
Wayfair (NYSE:W) is gearing up to release its second-quarter earnings before the market opens on August 4, with expectations of surpassing Street estimates for both sales and profitability. On Monday, Bank of America Securities analyst Curtis Nagle reiterated a Neutral rating on Wayfair, setting a price forecast of $60. Nagle's projection of $3.15 billion in second-quarter sales surpasses the Street's consensus of $3.12 billion. This more bullish outlook is attributed to stronger-than-expected industry trends, increased inventory availability driven by higher utilization of Wayfair's CastleGate system, and effective vendor-funded analyst's EBITDA estimate of $153 million also exceeds the Street's $146 million, fueled by expectations of higher gross profit dollars due to greater flow-through and leverage from Selling, Operations, Technology, General & Administrative expenses, particularly from a right-sizing of the company's tech headcount. Supporting these positive trends, Bank of America's aggregated credit and debit card data indicated a slight improvement in online furniture spending, which declined by 0.8% year-over-year in the second quarter, compared to a 1.6% decline in the first quarter. Nagle suggests that these improving trends could signify a pull-forward in demand and increased promotional spending, although this might potentially come at the expense of industry sales later in the year. He further noted that accelerating web and app trends suggest Wayfair is continuing to gain market share, driven by better product availability and vendor-funded promotions. Consequently, Nagle raised his second-quarter sales estimate by 1% to $3.15 billion and his EBITDA estimate by 2%. Looking ahead to the third quarter, Nagle also increased his sales estimate by 1% to $2.86 billion, which aligns closely with the Street's estimate of $2.87 billion. This adjustment reflects the better-than-expected performance of consumer spending and the broader furnishings category. Furthermore, concerns regarding tariffs appear to be easing following Vietnam's trade deal, despite an August 1 deadline. The extended Black Friday in July event also indicates a healthy supply on the site, likely as vendors increasingly leverage CastleGate. Nagle sees this event as an additional opportunity for Wayfair to drive incremental sales. However, he maintained his fourth-quarter estimates, primarily due to tougher year-over-year comparisons. While tariff concerns are abating, they remain a significant point of discussion for Wayfair. As such, topics on the upcoming earnings call are likely to revolve around the potential impact of tariffs on second-half 2025 trends and how vendors are navigating these challenges, particularly through CastleGate, vendor-funded promotions, and renegotiations. Nagle observed that the current share price already reflects the potential upside from easing tariffs and healthy supply trends. Price Action: Wayfair shares are trading lower by 1.51% to $55.59 at last check Monday. Read Next:Image via Shutterstock Latest Ratings for W Date Firm Action From To Feb 2022 Credit Suisse Maintains Outperform Feb 2022 RBC Capital Maintains Sector Perform Feb 2022 Needham Maintains Buy View More Analyst Ratings for W View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? WAYFAIR (W): Free Stock Analysis Report This article Wayfair Poised For Q2 Sales Beat On Strong Inventory, Vendor Promotions originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
34 minutes ago
- Yahoo
Brokers Suggest Investing in Bit Digital (BTBT): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Bit Digital, Inc. (BTBT). Bit Digital currently has an average brokerage recommendation (ABR) of 1.00, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by five brokerage firms. An ABR of 1.00 indicates Strong Buy. Of the five recommendations that derive the current ABR, five are Strong Buy, representing 100% of all recommendations. Brokerage Recommendation Trends for BTBT Check price target & stock forecast for Bit Digital here>>> While the ABR calls for buying Bit Digital, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential. Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation. In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement. Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision. Zacks Rank Should Not Be Confused With ABR Although both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether. The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them. On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks. Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements. Should You Invest in BTBT? In terms of earnings estimate revisions for Bit Digital, the Zacks Consensus Estimate for the current year has declined 90% over the past month to -$0.32. Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Bit Digital. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, it could be wise to take the Buy-equivalent ABR for Bit Digital with a grain of salt. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bit Digital, Inc. (BTBT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
an hour ago
- Yahoo
Why Globus Medical (GMED) Shares Are Trading Lower Today
What Happened? Shares of medical device company Globus Medical (NYSE:GMED) fell 6.6% in the afternoon session after the unexpected resignation of its President and CEO, Daniel Scavilla. The medical device company announced that Scavilla resigned effective July 18 to pursue another opportunity. He will be replaced by Keith Pfeil, who was promoted from his role as Chief Operating Officer and Chief Financial Officer. While the company reaffirmed its full-year 2025 guidance for revenue and earnings per share, the sudden change in the corner office appears to have unsettled investors, leading to the stock's decline. The departure introduces a level of uncertainty, even with a well-regarded internal successor and positive sales momentum. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Globus Medical? Access our full analysis report here, it's free. What Is The Market Telling Us Globus Medical's shares are not very volatile and have only had 7 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 2 months ago when the stock gained 5.8% on the news that the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cut U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains. However, President Trump clarified that tariffs could go "substantially higher" if a full deal with China wasn't reached during the 90-day pause, but not all the way back to the previous levels. Still, the agreement cooled fears of a prolonged trade war, helped stabilize expectations for global growth and trade flows and fueled renewed optimism. The optimism appeared concentrated in key trade-sensitive sectors, particularly technology, retail, and industrials, as lower tariffs reduce cost pressures and restore cross-border demand. Globus Medical is down 35.6% since the beginning of the year, and at $52.69 per share, it is trading 43.5% below its 52-week high of $93.32 from January 2025. Investors who bought $1,000 worth of Globus Medical's shares 5 years ago would now be looking at an investment worth $1,102. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Sign in to access your portfolio
